Postpartum Hemorrhage: Clinical Trials

52 trials for Postpartum Hemorrhage, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 10 unknown, 5 recruiting, 3 not yet recruiting. 52 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 352Completed 32, Unknown 10, Recruiting 5, Not yet recruiting 3, Withdrawn 2
Phase 27Completed 7

Follow Postpartum Hemorrhage: new trials by email Literature Review of Postpartum Hemorrhage trials Research Report on Postpartum Hemorrhage

Trials (filtered) newest first · largest first

All 52 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period
Phase 3RecruitingUniversity of Calgary88052026-06-042026-07-27
Investigating the Efficacy of Tranexamic Acid as a Prophylactic Agent in Reducing Postpartum Hemorrhage Among Patients Undergoing Cesarean Section in SQUH
tranexamic acid (1 g diluted in 100 mL of 0.9% saline, Normal (0.9%) saline - Post Partum Haemorrhage
Phase 3Not yet recruitingSultan Qaboos University882026-05-012026-04-01
EVE TRIAL , ALMA SYSTAM
Alma System - Postpartum Haemorrhage (PPH), PPH
Phase 3RecruitingResQ Medical Ltd502026-01-112026-03-30
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Sublingual Misoprostol, IV Oxytocin - Postpartum Hemorrhage
Phase 3RecruitingStony Brook University13582025-01-272025-05-04
Comparison Between Preoperative Vaginal and Postoperative Sublingual Misoprostol for Prevention of Postpartum Hemorrhage During Cesarean Section
Misoprostol - Postpartum Hemorrhage
Phase 3Not yet recruitingAssiut University4002025-01-012025-01-09
Prophylactic Amnioinfusion for Prevention of Postpartum Hemorrhage
Saline delivered using an intrauterine pressure catheter (IUPC) - Postpartum Hemorrhage
Phase 3Not yet recruitingThe University of Texas Health Science Center, Houston7002024-11-112024-11-18
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
Tranexamic acid injection, Oxytocin - Cesarean Section Complications, Tranexamic Acid
Phase 3UnknownCairo University1502024-10-012024-09-05
Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women At Higher Risk
Tranexamic acid, Placebo - Postpartum Hemorrhage
Phase 3RecruitingLondon School of Hygiene and Tropical Medicine300002024-04-222025-03-11
Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa
Tranexamic acid, 0.9% sodium chloride - Hemorrhage, Postpartum, Placenta Previa
Phase 3CompletedGuangzhou Medical University17322023-07-122025-03-27
Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Calcium chloride, Saline placebo - Uterine Atony, Uterine Atony With Hemorrhage
Phase 3CompletedStanford University1202022-04-042024-06-11
Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron] - Von Willebrand Diseases, Postpartum Hemorrhage
Phase 3CompletedNicoletta C Machin202021-06-042025-10-31
The Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Caesarean Section
Tranexamic acid injection, Normal saline placebo - Postpartum Hemorrhage
Phase 3CompletedUniversity of Zimbabwe12262021-03-232023-03-20
Sublingual vs Intrauterine MISOPROSTOL Plus Oxytocin Infusion for Prevention of Post-cesarean Hemorrhage in High Risk Pregnant Women: A Double-blind Placebo RCT
sublingual Misoprostol, Intrauterine Misoprostol - To Compare Efficacy Intrauterine vs Sublingual MISOPROSTOL in Addition to Oxytocin in Reducing Blood Loss of Post-cesarean Section in High Risk Women
Phase 3CompletedDepartment of Medical Services Ministry of Public Health of Thailand1352020-10-302021-09-13
TRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA
Tranexamic Acid / Sodium chloride - Postpartum Hemorrhage
Phase 3RecruitingUniversity Hospital, Bordeaux13802020-08-072025-02-10
Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section
Tranexamic acid, Normal saline - Postpartum Hemorrhage, Tranexamic Acid
Phase 3CompletedKK Women's and Children's Hospital2002020-06-232022-11-09
World Maternal Antifibrinolytic Trial_2
Tranexamic Acid, Placebo - Intrapartum - Moderate and Severe Anaemia
Phase 3CompletedLondon School of Hygiene and Tropical Medicine150682019-08-242024-01-10
Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
Tranexamic Acid, Placebo - Post Partum Hemorrhage, Fibrinolysis; Hemorrhage
Phase 2 / Phase 3CompletedUniversity of Texas Southwestern Medical Center1102019-06-172021-01-19
Tranexamic Acid for Prevention of Postpartum Haemorrhage: a Dose-finding Study
Tranexamic Acid - Post Partum Hemorrhage
Phase 3CompletedMount Sinai Hospital, Canada242018-07-112021-09-23
Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section
Tranexamic Acid, Oxytocin - Post Partum Hemorrhage
Phase 3CompletedUniversity of Zimbabwe5062018-04-082022-06-01
TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery
Tranexamic Acid Injectable Solution, Sodium Chloride 0.9% - Postpartum Hemorrhage
Phase 3CompletedUniversity Hospital, Bordeaux45742018-03-032026-05-12

Showing 20 of 52. Sign in to see all of them.

Narrower conditions

Hemorrhage (4)  ·  Placenta Previa (3)  ·  Pre-Eclampsia (2)  ·  Uterine Inertia (2)  ·  Anemia (1)  ·  Familial Primary Pulmonary Hypertension (1)  ·  Hyperthermia (1)  ·  Pain (1)  ·  Pulmonary Embolism (1)  ·  Thrombophilia (1)  ·  Venous Thromboembolism (1)  ·  Venous Thrombosis (1)  ·  von Willebrand Diseases (1)

Broader conditions

Female Urogenital Diseases and Pregnancy Complications (52)  ·  Obstetric Labor Complications (52)  ·  Pathologic Processes (52)  ·  Pathological Conditions, Signs and Symptoms (52)  ·  Pregnancy Complications (52)  ·  Puerperal Disorders (52)  ·  Urogenital Diseases (52)  ·  Uterine Hemorrhage (52)  ·  Hemorrhage (48)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Placenta Diseases (3)  ·  Dystocia (2)  ·  Hypertension, Pregnancy-Induced (2)  ·  Lung Diseases (2)

Interventions

Tranexamic Acid (18)  ·  Oxytocin (17)  ·  Misoprostol (11)  ·  Sodium Chloride (9)  ·  carbetocin (6)  ·  Saline Solution (3)  ·  Ergonovine (2)  ·  iron isomaltoside 1000 (2)  ·  Aspirin (1)  ·  Calcium Chloride (1)  ·  Control Groups (1)  ·  Dalteparin (1)  ·  Enoxaparin (1)  ·  Erythrocyte Transfusion (1)  ·  Fibrinogen (1)

Sponsors

Ain Shams University (4)  ·  Cairo University (4)  ·  London School of Hygiene and Tropical Medicine (3)  ·  Assiut University (2)  ·  Azienda U.S.L. 1 di Massa e Carrara (2)  ·  Gynuity Health Projects (2)  ·  Pharmacosmos A/S (2)  ·  Stanford University (2)  ·  University Hospital, Bordeaux (2)  ·  University of Zimbabwe (2)  ·  Yariv yogev (2)  ·  Benha University (1)  ·  Copenhagen University Hospital at Herlev (1)  ·  Department of Medical Services Ministry of Public Health of Thailand (1)  ·  Dr Meng-Li Lee (1)

Countries

Egypt (11)  ·  United States (7)  ·  Denmark (4)  ·  France (4)  ·  Canada (2)  ·  Israel (2)  ·  Nigeria (2)  ·  Tanzania (2)  ·  Zimbabwe (2)  ·  Argentina (1)  ·  Belgium (1)  ·  China (1)  ·  India (1)  ·  Ireland (1)  ·  Italy (1)

Top investigators

Yariv Yogev, professor (2)  ·  AbdelGany M Hassan (1)  ·  Ahmed N Afifi, MD (1)  ·  Ahmed N Shaker, MD (1)  ·  Alexander J Butwick, F.R.C.A. (1)  ·  Alicia V Aleman, MD (1)  ·  Amgad E. Abou-Gamrah, Ass.Prof. (1)  ·  Amon Agaba, PhD (1)  ·  Amy Brenner (1)  ·  Anne J. Wikkelsoe, MD (1)  ·  Antonio Ragusa, Dr (1)  ·  Arash Afshari, MD (1)  ·  Bellington Vwalika (1)  ·  Beverly Winikoff, MD, MPH (1)

Results publications

PMID 33232518, PMID 39162220, PMID 11207490, PMID 17567419, PMID 22805300, PMID 25369200, PMID 25586727, PMID 25588587, PMID 27188698, PMID 27350226, PMID 28317031, PMID 28413832, PMID 28456509, PMID 29558233, PMID 29743045, PMID 29879947, PMID 29945633, PMID 30134136, PMID 30322584, PMID 30514326, PMID 30594227, PMID 30606246, PMID 31962259, PMID 32005192, PMID 32492040, PMID 33169839, PMID 33913639, PMID 35038612, PMID 35303924, PMID 37106343, PMID 37664793, PMID 37690946, PMID 37917943, PMID 38044460, PMID 38873634, PMID 39461792, PMID 40448004, PMID 40902088, PMID 41624591, PMID 42128454

NIH funding

2009 (1), 2014 (1), 2017 (1), D43TW005492 (1), D43TW009343 (1)